Keratinocyte Transfection Reagent (Keratinocytes)

$184.00$1,104.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #1783)$184.00
1.5 ml (Catalog #1784)$368.00
8.0 ml (Catalog #7053)$1,104.00
SKU: KERA

Description

NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.

Transfection Reagent for Keratinocyte Cells (Keratinocytes)

  • Two component formulation enhances lipid mediated transfection efficiency
  • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
  • Kit includes Transfection Enhancer reagent and recommended transfection protocol
  • High transfection efficacy in the presence of serum
  • Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
  • Reproducible transfection results
  • Works well for standard reverse transfection and high-throughput applications
  • Download PowerPoint presentation for Keratinocyte cells transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems Keratinocyte Transfection Protocol: [PDF]

Download MSDS: [PDF]

Keratinocyte Cell Line:

Keratinocyte cells originate in the basal skin layer and grow densely outward through the layers of the epidermis. Keratinocyte cells are continuously shed and replaced from the outer layer  They are the most common type of skin cell. They are considered the building blocks of skin because they make keratin. Keratinocyte cells are tightly interwoven and form seams between the nerves and underlying tissues of the epidermis. This allows them to create a protective barrier to prevent infectious substances coming into the body through the skin. Keratinocytes are used to develop in vitro techniques to assess skin irritants. The cells are also the principal source of the proinflammatory cytokine IL-1 in the epidermis. Studies have found that Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. Keratinocyte cells constitute ~95% of the cells in the epidermis, and are sometimes divided into smaller cell types, such as basal keratinocytes, which are found more near the basal layer. There are multiple biomedical research applications using keratinocytes.

Data:

Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).

Keratinocyte-cells-transfection-protocol

Figure 2. Protein expression of Cyclophilin B in Keratinocyte cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into Keratinocyte cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
  • British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
  • Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Biosystems:

Altogen Biosystems transfection and electroporation products for life sciences and cancer research. Transfection reagents are developed for individual cancer cell line and transfection protocols are optimized for maximum delivery efficiency. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in  vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1783)
  • 1.5 ml (Catalog #1784)
  • 8.0 ml (Catalog #7053)

Additional information

Kit Size (Volume)

0.5 ml (Catalog #1783), 1.5 ml (Catalog #1784), 8.0 ml (Catalog #7053)